Dendreon Announces FDA's Cellular, Tissue And Gene Therapies Advisory Committee To Review Provenge(R) For The Treatment Of Prostate Cancer
Fri, 02 Mar 2007 08:00 AM EST
... Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. [click link for full article] ...
Related Topics
- Prostate Cancer
- Prostate
- Electromagnetic Fields
- Treatments
- Alternative Medicine
- Connective Tissue
- Bioethics
- Bone Cancer
- Biopsy of the Prostate
- Treatment
- Cancers
- Prostate Diseases
- Genes and Gene Therapy
- Metastatic Cancer
- BRCA
- Soft Tissue Sarcoma
- Chemotherapy
- Kidney Cancer
- Pancreatic Cancer
- Esophageal Cancer

Not Signed In -


